Clinical Benefit of Antiangiogenic Therapy in Advanced and Metastatic Chondrosarcoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2017 Aug 31

PMID 28852958

Citations 23

Authors

Robin L Jones

Daniela Katz

Elizabeth T Loggers

Darin Davidson

Eve T Rodler

Seth M Pollack

Affiliations

Soon will be listed here.

Abstract

Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma. Ten patients were identified; seven with conventional, one each with clear cell, extraskeletal mesenchymal chondrosarcoma and extraskeletal myxoid chondrosarcoma. The median progression-free survival for patients with conventional and clear cell sarcoma was 22.6 months. Median overall survival has not been met. Antiangiogenic therapy was well tolerated in this series of patients. Our retrospective data suggest that antiangiogenic therapy can provide prolonged clinical benefit in advanced chondrosarcoma patients. Further prospective trials are required to precisely define the role of this class of agent in advanced chondrosarcoma.

Citing Articles

Advancing Systemic Therapy in Chondrosarcoma: New Horizons.

Li K, Gulia A, Duffaud F, Jones R Oncol Ther. 2024; 13(1):1-9.

PMID: 39652252 PMC: 11880466. DOI: 10.1007/s40487-024-00317-z.

Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies.

Agosti E, Zeppieri M, Antonietti S, Ius T, Fontanella M, Panciani P J Pers Med. 2024; 14(3).

PMID: 38541003 PMC: 10971225. DOI: 10.3390/jpm14030261.

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.

Setola E, Benini S, Righi A, Gamberi G, Carretta E, Ferrari C BMC Cancer. 2023; 23(1):907.

PMID: 37752419 PMC: 10521511. DOI: 10.1186/s12885-023-11396-y.

Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies.

Walter S, Knoll P, Eysel P, Quaas A, Gaisendrees C, Nissler R Cancers (Basel). 2023; 15(9).

PMID: 37174021 PMC: 10177611. DOI: 10.3390/cancers15092556.

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions.

Gilbert A, Tudor M, Montanari J, Commenchail K, Savu D, Lesueur P Cancers (Basel). 2023; 15(7).

PMID: 37046623 PMC: 10093143. DOI: 10.3390/cancers15071962.

References

McGough R, Aswad B, Terek R . Pathologic neovascularization in cartilage tumors. Clin Orthop Relat Res. 2002; (397):76-82. DOI: 10.1097/00003086-200204000-00011. View

Klenke F, Abdollahi A, Bertl E, Gebhard M, Ewerbeck V, Huber P . Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer. 2007; 7:49. PMC: 1832206. DOI: 10.1186/1471-2407-7-49. View

Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani J . Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013; 9(6):789-95. DOI: 10.2217/fon.13.68. View

Furumatsu T, Nishida K, Kawai A, Namba M, Inoue H, Ninomiya Y . Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. Int J Cancer. 2002; 97(3):313-22. DOI: 10.1002/ijc.1607. View

van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

Stacchiotti S, Pantaleo M, Astolfi A, Dagrada G, Negri T, Dei Tos A . Activity of sunitinib in extraskeletal myxoid chondrosarcoma. Eur J Cancer. 2014; 50(9):1657-64. DOI: 10.1016/j.ejca.2014.03.013. View

Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C . Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol. 2013; 24(11):2916-22. PMC: 3811906. DOI: 10.1093/annonc/mdt374. View

Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5. View

Morioka H, Weissbach L, Vogel T, Nielsen G, Faircloth G, Shao L . Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res. 2003; 9(3):1211-7. View

10.

Gelderblom H, Hogendoorn P, Dijkstra S, van Rijswijk C, Krol A, Taminiau A . The clinical approach towards chondrosarcoma. Oncologist. 2008; 13(3):320-9. DOI: 10.1634/theoncologist.2007-0237. View

11.

Levine A, Tulpule A, Quinn D, Gorospe 3rd G, Smith D, Hornor L . Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006; 24(11):1712-9. DOI: 10.1200/JCO.2005.03.4801. View

12.

Ayala G, Liu C, Nicosia R, Horowitz S, Lackman R . Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol. 2000; 31(3):341-6. DOI: 10.1016/s0046-8177(00)80248-8. View

13.

Cintra F, Etchebehere M, Goncalves J, Cassone A, Amstalden E . Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation. Clinics (Sao Paulo). 2011; 66(9):1591-6. PMC: 3164410. DOI: 10.1590/s1807-59322011000900015. View

14.

Katz D, Azraq Y, Eleyan F, Gill S, Peretz T, Merimsky O . Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis. BMC Cancer. 2016; 16:616. PMC: 4977830. DOI: 10.1186/s12885-016-2618-1. View

15.

Fox E, Patel S, Wathen J, Schuetze S, Chawla S, Harmon D . Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012; 17(3):321. PMC: 3316916. DOI: 10.1634/theoncologist.2010-0265. View